Einstein-Rockefeller-CUNY Center for AIDS Research

爱因斯坦-洛克菲勒-纽约市立大学艾滋病研究中心

• 批准号: 9922220
• 负责人: HARRIS GOLDSTEIN
• 金额: $ 289.44万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9922220
• 关键词: AIDS prevention; AIDS/HIV problem; Academia; Acquired Immunodeficiency Syndrome; Adherence; Area; Back; Basic Science; Behavioral; Behavioral Research; Behavioral Sciences; Biological Markers; Cells; Centers for Disease Control and Prevention (U.S.); Cities; Clinical; Clinical Research; Collaborations; Communities; Community Health; Development; Discipline; Disease Progression; Early Diagnosis; Epidemic; Epidemiology; Financial Support; Government; HIV; HIV Infections; HIV Seronegativity; HIV Seropositivity; HIV diagnosis; HIV therapy; HIV-1; Health Services Accessibility; Health system; Immunologic Adjuvants; Improve Access; Incidence; Individual; Infection; Infrastructure; Institution; Interdisciplinary Study; Interleukin-15; Leadership; Link; Medicine; Mentors; Methods; Mission; Modality; New York; New York City; Outcome; Outcomes Research; Patients; Persons; Population; Prevention; Prevention strategy; Preventive; Process; Prophylactic treatment; Public Health; Public Health Schools; Reporting; Research; Research Personnel; Resource Sharing; Resources; Science; Services; Strategic Planning; Structure; Technology; Testing; Translating; Translational Research; Treatment outcome; United States; United States National Institutes of Health; Universities; Vaginal Ring; Viral; antiretroviral therapy; base; bench to bedside; career; college; community partnership; design; disease transmission; epidemiology study; forging; health disparity; high risk; high risk population; implementation research; implementation science; implementation strategy; improved; improved outcome; innovation; multidisciplinary; neutralizing antibody; next generation; novel; novel therapeutics; patient population; population health; pre-clinical research; prevent; programs; recruit; research study; skills; social disparities; synergism; topical antiretroviral; transmission process; working group

PROJECT SUMMARY As the AIDS research community and public health systems locally, nationally and globally focus efforts on preventing HIV transmission and ending the epidemic, it is critical to integrate our efforts across institutions and disciplines, sharing resources among many researchers to achieve the greatest gain in scientific understanding. In the current absence of a CFAR in New York, an epicenter of HIV infection, our strategic planning process made clear that the greatest contribution of a New York City-based CFAR would be achieved by reaching out to other institutions. Thus, the Einstein/Rockefeller/CUNY (ERC)-CFAR has created a highly synergistic new partnership of non-overlapping complementary resources, linking a strong basic and clinical research institution (Einstein)`with a large patient base, a globally pre-eminent basic science institution (Rockefeller), and a strong public health/implementation science institution (CUNY) to catalyze research to prevent HIV and end the epidemic. We are structured to collaborate extensively across disciplines and institutions to drive a trans-institutional, interdisciplinary, and coordinated research agenda by ERC-CFAR investigators focused on “bench to bedside to community and back to the bench” research, and translating science into reality by assessing implementation of strategies and treatments shown to be efficacious in clinical and bench research. The ERC-CFAR will stimulate, coordinate, and support an integrated multidisciplinary research agenda to achieve our mission, to arrest the AIDS epidemic, through improving utilization of current treatments and developing new therapies, such as potent broadly neutralizing antibodies, for prevention, reducing the incidence of new infections; treatment, improving treatment outcomes among infected individuals; and eradication of HIV reservoirs. The ERC-CFAR will develop new research aimed at ending the epidemic by implementing five Specific Aims: 1) To empower a proactive, inclusive, and integrated program leadership approach to drive a trans-institutional, interdisciplinary, and coordinated research agenda by ERC-CFAR investigators focused on “bench to bedside to community and back to the bench” research to reduce HIV incidence, improve access to treatment, promote adherence, improve outcomes and eradicate HIV reservoirs to arrest the AIDS epidemic; 2) To utilize three Scientific Cores to support and advance the basic, clinical, behavioral, epidemiological, translational, and implementation research of the ERC-CFAR investigators; 3) To provide the intellectual, technical, and financial support to advance the careers of the next generation of young, innovative, and interdisciplinary HIV/AIDS investigators, while recruiting established investigators into HIV/AIDS research and forging new collaborations across institutions; 4) To build an innovative community partnership with representatives from government, community, and academia, to participate in collaborative studies to optimize HIV diagnosis, treatment, and prevention outcomes. 5) Identify pioneering scientific initiatives aligned with those identified by the Office of AIDS Research (OAR) Trans-NIH Strategic Plan for HIV- related research and actuate them by assembling interdisciplinary research/community ERC-CFAR teams and creative collaborations locally with other NYC HIV investigators and nationally with other CFARs.

项目总结 随着艾滋病研究界和地方、国家和全球公共卫生系统集中努力 关于预防艾滋病毒传播和结束这一流行病，至关重要的是将我们的努力整合到各个机构 和学科，在许多研究人员之间共享资源，以实现科学上的最大收益 理解。在艾滋病毒感染的中心纽约目前没有CFAR的情况下，我们的战略 规划过程清楚地表明，总部设在纽约的CFAR将做出最大贡献 通过联系其他机构。因此，爱因斯坦/洛克菲勒/纽约大学(ERC)-CFAR创造了一个高度 协同的新型伙伴关系互不重叠，资源互补，链接强大的基础和临床 研究机构(爱因斯坦)拥有庞大的患者基础，是全球领先的基础科学机构 (洛克菲勒)，和一个强大的公共卫生/实施科学机构(CUNY)，以催化研究 预防艾滋病毒，结束疫情。我们的结构是跨学科广泛协作， 机构推动ERC-CFAR跨机构、跨学科和协调的研究议程 调查人员将重点放在“板凳到床边再到社区再回到板凳”的研究上，并进行了翻译 通过评估在临床上被证明有效的策略和治疗的实施，将科学转化为现实 和板凳研究。ERC-CFAR将刺激、协调和支持一个综合的多学科 研究议程实现我们的使命，通过改善对现有资源的利用来遏制艾滋病的流行 治疗和开发新的治疗方法，如有效的广谱中和抗体，用于预防， 减少新感染的发生率；治疗，改善感染者的治疗结果； 和根除艾滋病毒携带者。ERC-CFAR将开发新的研究，旨在通过以下方式结束疫情 实施五个具体目标：1)增强主动、包容和综合的计划领导力 ERC-CFAR推动跨机构、跨学科和协调的研究议程的方法 调查人员将重点放在了减少艾滋病毒的研究上，即从长凳到床边，再到社区，再回到长凳上 发病率、改善治疗机会、促进坚持、改善结果和根除艾滋病毒携带者 遏制艾滋病流行；2)利用三大科学核心，支持和推进基础、临床、 ERC-CFAR调查员的行为、流行病学、翻译和实施研究；3) 提供智力、技术和财政支持，以推动下一代年轻人的职业生涯， 创新的、跨学科的艾滋病毒/艾滋病调查人员，同时招募资深调查人员进入 艾滋病毒/艾滋病研究和跨机构建立新的合作；4)建立创新社区 与政府、社区和学术界的代表建立伙伴关系，参与合作 优化艾滋病毒诊断、治疗和预防成果的研究。5)确定开创性的科学 与艾滋病研究办公室(OAR)确定的跨NIH艾滋病毒战略计划相一致的倡议- 相关研究，并通过集合跨学科研究/社区ERC-CFAR团队和 在当地与纽约市其他艾滋病毒调查人员以及全国与其他CFAR进行创造性合作。